Pompe disease is a rare and deadly disease that can manifest at any age of life, including infancy.
It is characterized by debilitating muscle weakness that progresses over time and arises from a mutation in the acid alpha glucosidase enzyme that is responsible for breakdown of glycogen in muscle cells.
ABX1100 is a novel approach to treating Pompe disease that aims to reduce glycogen buildup in the muscles.
The FDA awards RPD designation to drugs treating rare pediatric diseases that are serious or life-threatening and affect patients from birth to 18 years of age.
Sponsors that receive RPD from the FDA are entitled to receive a Pediatric Review Voucher upon approval in a pediatric disease indication, giving the holder access to a priority review, reduced review time and potential expedited product approval.
Based in Philadelphia, Aro Biotherapeutics is a biotechnology company pioneering the development of tissue-targeted genetic medicines with a platform based on a proprietary protein technology called Centyrins.
The company is developing a wholly-owned pipeline of Centyrin-based therapeutic candidates and is working with industry partners to leverage Centyrins for tissue-specific targeting of therapeutics for a diverse set of diseases.
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial